Neuromyelitis Optica Spectrum Disorder
Conditions
Keywords
Neuromyelitis Optica Spectrum Disorder, BTK inhibitors, Orelabrutinib
Brief summary
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely disabling disease. AQP4-IgG positive NMOSD is related to a specific aquaporin 4 antibody (AQP4 IgG) produced by mature B cells. BTK is a key kinase in B cell receptor signal transduction pathway. Abnormal activation of BTK related signaling pathway can lead to autoantibody production and autoimmune diseases. Therefore, BTK can be developed as a new target for autoimmune diseases.
Detailed description
Approximately 23 subjects will be enrolled. Experimental drug treatment: Orelabrutinib, 50mg, orally, once a day. The subject will come to visit at week 0, 1, 2, 4, 8, 12, 16, 20, 24, 36, 48 and safety follow up visit which is planed 28 days after last administration. Baseline patient assessment: 1. Baseline examination: vital signs, physical examination, blood routine examination, urine routine examination, liver and kidney function, coagulation function, thyroid function, HIV, HCV, HBV virus test, tuberculosis test, chest X-ray, ECG and pregnancy test. 2. Functional disability assessment: Expanded Disability Status Scale (EDSS) score and low contrast vision (LCVA) score. 3. EQ5D scale evaluation. 4. Serum AQP4-IgG titer, neuro filament light chain, T/B/NK cell count, Immunoglobulin (IgG, IgA and IgM)
Interventions
DRUGOrelabrutinib
Orelabrutinib, orally, 50 mg QD
Sponsors
Beijing InnoCare Pharma Tech Co., Ltd.
GCP ClinPlus Co., Ltd.
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\) 18-75 years old (inclusive) at the time of signing the informed consent form * 2)Diagnosed with AQP4-IgG positive NMOSD in accordance with 2015 IPND diagnostic criteria. * 3)Relapse ≥ 2 within 1 year before screening, and at least 1 relapse within 6 months before screening * 4)If the subject has stable steroids treatment (≤ 7.5mg prednisone, or equivalent dose of steroids), the treatment needs to be stable more than 1 month before starting the study drug treatment. * 5)EDSS ≤7.5 at screening * 6)Negative pregnancy test for female of childbearing potential at screening * 7)Understood the study procedure and voluntarily signed written informed consent
Exclusion criteria
* 1\) History of serious heart, lung, liver, kidney, blood disease, etc. * 2\) Any major infection judged by the investigator requiring hospitalization and parenteral antimicrobial treatment within 1 month before screening * 3\) History of episodes of herpes zoster ≥ 2 or disseminated herpes zoster ≥ 1 * 4\) History of or having any of the following medication / treatment: ① Received BTK inhibitor at any time in the past; ② B-cell targeted therapy within 12 weeks before the first dose; ③ Received biological agents within 12 weeks before the first dose; ④ Received live virus vaccine or live attenuated vaccine within 8 weeks before the first dose; ⑤ Received steroids treatment for other diseases within 6 months before screening, the dosage \> 20mg / day for more than 21 days; ⑥ Used a study drug or other experimental treatment within 4 weeks before screening or 5 half-lives, or participating in any other intervention clinical trial. * 5\) During screening or baseline examination, laboratory results meet the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Annualized relapse rate at week 48 compared with that before baseline. | week 48 | Annualized relapse rate at week 48 compared with that before baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the expanded disability status scale (EDSS) score from baseline | weeks 4, 12, 24, 36 and 48 | Changes in the expanded disability status scale (EDSS) score from baseline at weeks 4, 12, 24, 36 and 48; |
| Changes in low contrast visual acuity score (LCVA) from baseline | weeks 4, 12, 24, 36 and 48 | Changes in low contrast visual acuity score (LCVA) from baseline at weeks 4, 12, 24, 36 and 48; |
| Changes in EQ5D scores from baseline | weeks 12, 24, 36 and 48 | Changes in EQ5D scores from baseline at weeks 12, 24, 36 and 48; |
| Proportion of patients without relapse | weeks 24 and 48 | Proportion of patients without relapse at weeks 24 and 48; |
| Changes in absolute value of peripheral blood B cell count and immunoglobulin (IgA, IgM, IgG) from baseline | weeks 4, 12, 24, 36 and 48 | Changes in absolute value of peripheral blood B cell count and immunoglobulin (IgA, IgM, IgG) at weeks 4, 12, 24, 36 and 48 from baseline; |
| Percentage of patients who withdraw from the study due to adverse events. | weeks1, 2, 4, 8, 12, 16, 20, 24, 36 , 48 | Percentage of patients who withdraw from the study due to adverse events. |
| Changes in serum AQP4-IgG titer and neurofilament light chain protein level from baseline | weeks 4, 12, 24, 36 and 48 | Changes in serum AQP4-IgG titer and neurofilament light chain protein level from baseline at weeks 4, 12, 24, 36 and 48; |
Countries
China
Contacts
Primary ContactYan Xu, Doctor
Outcome results
None listed